Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy

Ecopipam, an investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designations.  The acquisition expands Teva’s innovative pipeline in a specialized area of neuroscience with significant unmet need and is expected to support near- and long-term growth.  At […]